A peek at Regenxbio Inc (RGNX): Who has invested in It?

Regenxbio Inc (NASDAQ: RGNX) is -9.25% lower on its value in year-to-date trading and has touched a low of $11.83 and a high of $25.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RGNX stock was last observed hovering at around $14.57 in the last trading session, with the day’s gains setting it 1.72%.

Currently trading at $16.29, the stock is 19.71% and -2.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 11.81% at the moment leaves the stock -8.36% off its SMA200. RGNX registered -32.18% loss for a year compared to 6-month loss of -10.00%. The firm has a 50-day simple moving average (SMA 50) of $5.09 and a 200-day simple moving average (SMA200) of -$2.16.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a 11.04% gain in the last 1 month and extending the period to 3 months gives it a -0.91%, and is 28.47% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.17% over the week and 6.94% over the month.

Regenxbio Inc (RGNX) has around 401 employees, a market worth around $716.60M and $99.37M in sales. Profit margin for the company is -262.18%. Distance from 52-week low is 37.70% and -35.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.27%).

Regenxbio Inc quarterly earnings per share for the current quarter are estimated at -$1.25 with sales reaching $35.98M over the same period.The EPS is expected to grow by 15.75% this year, but quarterly earnings will post -7.70% year-over-year. Quarterly sales are estimated to grow 14.80% in year-over-year returns.

243 institutions hold shares in Regenxbio Inc (RGNX), with institutional investors hold 101.43% of the company’s shares. The shares outstanding are 43.30M, and float is at 39.29M with Short Float at 11.23%. Institutions hold 93.15% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 8.27 million shares valued at $165.3 million. The investor’s holdings represent 18.81% of the RGNX Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 4.34 million shares valued at $86.76 million to account for 9.87% of the shares outstanding. The other top investors are JP Morgan Chase & Company which holds 3.7 million shares representing 8.42% and valued at over $73.99 million, while State Street Corporation holds 6.28% of the shares totaling 2.76 million with a market value of $55.21 million.

Regenxbio Inc (RGNX) Insider Activity

A total of 0 insider transactions have happened at Regenxbio Inc (RGNX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Mills Kenneth T., the company’s President and CEO. SEC filings show that Mills Kenneth T. sold 45,000 shares of the company’s common stock on Jan 16 at a price of $15.18 per share for a total of $0.68 million. Following the sale, the insider now owns 0.41 million shares.

Regenxbio Inc disclosed in a document filed with the SEC on Jan 03 that PAKOLA STEVE (Chief Medical Officer) sold a total of 17,237 shares of the company’s common stock. The trade occurred on Jan 03 and was made at $17.39 per share for $0.3 million. Following the transaction, the insider now directly holds 0.11 million shares of the RGNX stock.

Still, SEC filings show that on Dec 19, Mills Kenneth T. (President and CEO) disposed off 45,000 shares at an average price of $19.68 for $0.89 million. The insider now directly holds 355,289 shares of Regenxbio Inc (RGNX).